LENZ

LENZ Therapeutics, Inc.

Healthcare · $101M market cap

Verdict

We can't put a fair value on LENZ right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth2.9% a year✗
Sales growth8.4% a year✗
Free cash flow growth—?
Return on invested capital-29.5%✗

Follow LENZ

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Oct 29, 2026: no open-market purchases, 12 sales worth $36.5M and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Sales

Other filings

Questions about LENZ

Are insiders buying LENZ?

Since Oct 29, 2026: no open-market purchases, 12 sales worth $36.5M and 1 other filing (stock awards, tax withholding and similar).

How can I check LENZ's value myself?

Use the free Sticker Price calculator, already filled with LENZ's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →

Similar stocks · Biotechnology

About LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 3, 2026. How the Payback Price works